Entities / Company
Amgen.
American multinational biopharmaceutical company
- Reports this week
- 8
- Active events
- 5
- Connections
- 491
What's happening
Reports per dayLast 90 days
90 days agoDrag either end to show only events that began in that periodToday
Active this week
-
Laurus Labs is shifting focus from building to filling capacity and may participate in Amgen's supply chain.Some support1 report
-
Reports on market moves involving Nike, Amgen, and Investopedia, amidst the ongoing Iran conflict.Some support1 report
-
Amgen and Merck are currently competing against each other in the market for investor capital.Some support4 reports
-
Amgen Inc. trades on the NASDAQ stock exchange.Well supported22 reports
-
A guide on retirement income strategies was provided, noting strong dividend coverage cushions for Procter & Gamble and Amgen.Some support1 report
Earlier this month
-
A group of major pharmaceutical companies, including AbbVie, Bristol-Myers Squibb, Amgen, Pfizer, Moderna, and Merck, are noted as peers operating in the highly regulated pharmaceutical sector.Some support4 reports1 development inside
-
Major pharmaceutical companies are competing for investment capital.Some support1 report
-
Amgen and Eli Lilly committed to adopting Veeva's CRM platform, while Jim Cramer discussed Veeva's recovery from AI fears.Some support1 report
-
Amgen announced funding initiatives aimed at promoting vision care.Some support1 report
-
Major pharmaceutical companies, including Pfizer, Amgen, Eli Lilly, and Novo Nordisk, are leading the market in next-generation GLP-1 drugs for weight loss and diabetes.Well supported11 reports5 developments inside
-
Several financial firms acquired or boosted their holdings in Amgen shares on October 7, 2026.Some support1 report
-
AbbVie, Amgen, Micron Technology, and NetApp all showed strength in the stock market on October 7, 2026.Some support1 report
-
Companies including ConocoPhillips, Amgen, Procter & Gamble, Coca-Cola, Texas Instruments, and Qualcomm are noted as part of the SCHD portfolio.Well supported3 reports
-
Amgen, City of Hope, and the California Community Foundation are involved in a life sciences and bioscience economic summit held in Downtown Los Angeles.Some support1 report
-
Geode Capital Management increased its stake in Amgen stock and filed the disclosure with the SEC.Some support2 reports
-
AI stocks are benefiting from Trump-era tariffs, with Morningstar and ClearBridge providing market analysis on growth and upside potential.Some support13 reports10 developments inside
-
Trump's oil and gas pledges benefit US stocks, specifically impacting Pfizer.Well supported131 reports40 developments inside
-
Intuit provides financial management services including TurboTax, Mailchimp, and Credit Karma, alongside developing innovative medicines.Well supported10 reports1 development inside
-
Royalty Pharma acquired a royalty interest in Amgen's drug Imdelltra.Well supported9 reports
-
Trump's tariff plan caused markets to tank, affecting company Flo.Some support79 reports12 developments inside
-
Pharmaceutical companies are adopting AI for clinical data gathering, product promotion, and prototyping.Well supported4 reports12 developments inside
-
The EPA recognized Amgen's green chemistry efforts, involving VP Margaret Faul, who previously worked at Eli Lilly.Some support1 report
-
Sanofi removed Sjögren's from frexalimab and Novartis discontinued iscalimab in Sjögren's.Some support1 report
-
RFK Jr.'s appointment as HHS Secretary is creating pressure as Medicare price setting and Part D redesign impact the sales and operations of major pharmaceutical companies including Pfizer, Amgen, J&J, Merck, and Eli Lilly.Speculative1 report2 developments inside
-
Amgen and Deloitte are cited as examples of companies undergoing industry transformation.Some support1 report
-
Amgen acquired Horizon Therapeutics, a company whose portfolio included a drug discovered by AstraZeneca.Some support1 report
-
Berkshire Hathaway disclosed a large share purchase of Amgen on September 22, 2026.Some support1 report
-
Pfizer, Merck, and Amgen are large-cap drugmakers with significant operations in the United States.Some support1 report1 development inside
One to three months ago
-
Several biotech companies reported clinical trial setbacks, including Argenx and Immunovant, while Sling Therapeutics' drug was compared to offerings from Viridian and Amgen.Some support1 report
-
Both Amdocs and Amgen are currently subject to analyst reviews.Some support1 report
-
Multiple companies, including Eli Lilly, Amgen, Ionis, and Novartis, are developing advanced experimental drugs for heart disease, including those targeting Lp(a).Some support2 reports7 developments inside
-
Analyst upgrades and downgrades are affecting the stock performance of Amgen and CF Industries.Some support1 report
-
Amgen and Novartis have developed similar drugs aimed at treating heart conditions.Some support6 reports2 developments inside
-
A rival's trial failure has challenged the shared scientific hypothesis between Amgen and Novartis.Some support1 report
-
Novartis' drug failure has negatively impacted Amgen's financial outlook.Some support2 reports1 development inside
-
The market is reacting to the news of Novartis' drug trial failures, specifically impacting Amgen's stock performance on the Nasdaq exchange.Some support2 reports
-
Amgen discusses biotech and pharma trends with Wells Fargo, where Thomas Dittrich serves as the company's Chief Financial Officer.Some support1 report
-
Cantor Fitzgerald and other analyst firms issued ratings on Amgen stock, which is listed on the Nasdaq exchange.Some support1 report
-
Barclays raises S&P 500 target, Amgen stock slumps after trial failure, and oil prices rise due to escalating Middle East hostilities.Some support1 report
-
Novartis and Amgen stocks are declining, putting pressure on the Dow Jones Industrial Average due to their shared focus on cholesterol-targeting drugs.Some support1 report
-
Reports on the top holdings of various healthcare and biotech ETFs, listing major pharmaceutical companies like Eli Lilly, Amgen, and Johnson & Johnson.Some support1 report
-
Amgen and AstraZeneca partnered on a Phase 3 CROSSING trial for the drug TEZSPIRE.Some support3 reports1 development inside
-
Amgen and AstraZeneca co-developed the severe asthma drug TEZSPIRE, prompting an analyst to raise the price target.Some support2 reports
-
Amgen's stock price was impacted by clinical trial disappointments, while Brent crude influenced S&P 500 market movement.Some support1 report
-
Amgen and AstraZeneca announced a collaborative development of a combination therapy.Some support2 reports1 development inside
-
Joint drug trial success boosts Amgen stock.Some support1 report
-
Geopolitical risk drives energy prices due to Iranian regime action, while clinical failures impact biotech stocks and Dell Technologies gains investor favor.Some support1 report
-
GSK and Amgen are major biopharma players.Some support1 report
-
Amgen and Eli Lilly offer treatments for thyroid eye disease, with Lilly's pipeline requiring regulatory approval.Some support6 reports1 development inside
-
The biotech sector is experiencing a downturn due to drug failures, impacting companies like Amgen and Eli Lilly.Some support1 report
-
Market activity was monitored by representatives involving Amgen and Broadcom.Some support3 reports
-
Amgen benefits from Novartis/Ionis Phase 3 research, Mizuho raised price targets, and the company faces a tax dispute resolution timeline.Some support4 reports
-
Both Microsoft and Amgen are major dividend payers currently under market scrutiny.Some support1 report1 development inside
-
Amgen and Microsoft are top holdings in an ETF.Some support1 report
-
Norges Bank, Cantor Fitzgerald, Bank of America, and Scotiabank announced new stakes and target price boosts for Amgen.Some support2 reports
-
Amgen presented findings at the European Society of Cardiology Congress in Munich.Some support1 report
-
Amgen filed required reports with the Securities and Exchange Commission on June 16, 2026.Well supported6 reports1 development inside
-
Mikey Taylor graduated from Newbury Park High School and is running for Thousand Oaks City Council, while Karen Arreola worked at Amgen.Some support1 report
-
Healthcare stocks surged to record highs on August 19, 2026, amid market excitement over drug breakthroughs involving Moderna, Amgen, and Merck.Some support2 reports
-
Amgen is reportedly interested in BioCryst Pharmaceuticals, which operates in the rare-disease market, as a potential acquisition target.Some support1 report
No events began in the chosen period. Widen it, or reset.
What's reaching Amgen
Events traced to Amgen, step by step, newest first- Novo Nordisk's GLP-1 leadership intensifies competition for AmgenNovo Nordisk's GLP-1 dominance increases competitive pressure on AmgenLikely
- Sanofi's expanded Dupixent access increases competition for AmgenSanofi's expanded Dupixent access increases competition for AmgenPossible
- Increased biotech investment in Boston may raise competitive pressure on AmgenIncreased biotech investment in Boston may raise competitive pressure on AmgenPossible
- Pluvicto access barriers may shift competitive dynamics for AmgenPluvicto access barriers may shift competitive dynamics for AmgenPossible
Around Amgen this week
News at the entities that move Amgen most-
FDA StructuralTraceLink advances multinational compliance roadmaps in Egypt and Ethiopia while addressing FDA's transition to 12-digit National Drug Code.Moves Amgen
-
Norges Bank TransactionalNorges Bank acquired a new position in Manulife Financial.Moves Amgen
-
Securities and Exchange Commission StructuralCitigroup reaffirmed an outperform rating on Barrett Business Services, Inc. while the SEC mandated 13F filings for investment disclosures.Moves Amgen
-
Morgan Stanley OperationalKlook is pursuing an IPO, with Goldman Sachs and Morgan Stanley involved in the advisory process, amidst market headwinds from Trump's policies.Moves Amgen
-
Quantinuum StructuralMorgan Stanley upgraded Quantinuum stock, while Joseph Moore maintained an equal-weight rating on IonQ.Moves Amgen
-
Colorado StructuralChris Cook family moved from Kansas to Thornton, while Kansas, Colorado, and Arizona have legislative action on gender-affirming care.Moves Amgen
Connections
The 40 strongest of 491, analyzed from the reporting. The bars show how strongly a change on one side reaches the other.-
Novartis Operational
Amgen and Novartis are direct competitors in the biopharmaceutical market, where clinical trial outcomes and market events of one significantly impact the other's stock performance and risk profile.
-
Nasdaq Structural
Amgen is a publicly traded company whose listing and trading are formally hosted on the Nasdaq stock exchange.
-
Horizon Therapeutics Structural
Amgen acquired Horizon Therapeutics, making it a subsidiary and integrating its rare disease portfolio.
-
Thomas Dittrich Structural
Thomas Dittrich serves as the Chief Financial Officer of Amgen.
-
Genome Valley Structural
Amgen is establishing a dedicated Science and Innovation Center within the Genome Valley ecosystem.
-
Novo Nordisk Operational
Amgen and Novo Nordisk are direct competitors in the GLP-1 and obesity drug markets.
-
Onyx Pharmaceuticals Structural
Amgen acquired Onyx Pharmaceuticals for $10 billion, establishing a parent-subsidiary relationship.
-
Pfizer Operational
Pfizer and Amgen are major pharmaceutical competitors actively vying for market share in specialized therapeutic areas, including GLP-1 drugs and biosimilars.
Show all 40 connections
-
Norges Bank Transactional
Norges Bank purchased a new stake in Amgen stock.
-
Jay Bradner Structural
Jay Bradner holds an executive vice president role in R&D at Amgen.
-
SEC Structural
Amgen operates under formal financial reporting and disclosure requirements mandated by the SEC.
-
Jyothis George Structural
Jyothis George held a Global Medical Vice President role at Amgen and drove strategic decision making for the company.
-
FDA Structural
The FDA formally regulates Amgen's drug development, approval, and market use, dictating its operational scope.
-
AbbVie Operational
AbbVie and Amgen are direct competitors and peers within the biopharmaceutical sector, particularly in the psoriatic arthritis market.
-
Cardinal Health Structural
Amgen relies on Cardinal Health as a critical partner for product distribution and revenue concentration.
-
Securities and Exchange Commission Structural
Amgen is subject to mandatory regulatory filings and oversight by the Securities and Exchange Commission.
-
Johnson & Johnson Operational
Johnson & Johnson and Amgen actively compete in the biopharma sector, particularly in immunology and bispecific antibodies.
-
Morgan Stanley Operational
Morgan Stanley actively monitors Amgen's clinical data and issues research reports, influencing its market valuation and price targets.
-
Cencora Structural
Amgen relies on Cencora as a critical distributor and wholesaler for its pharmaceutical products.
-
Merck Operational
Amgen and Merck are direct competitors in the biosimilar market and compete for investor capital and market growth.
-
Eli Lilly and Company Operational
Both companies are direct competitors in advanced drug markets, specializing in GLP-1 agonists, obesity treatments, and Lp(a) reduction.
-
Royalty Pharma Structural
Royalty Pharma holds royalty rights to Amgen's drugs, establishing a persistent financial dependency on Amgen's sales.
-
Quantinuum Structural
Amgen utilizes Quantinuum's quantum computing platform as a critical component for its advanced operations.
-
Colorado Structural
Colorado state regulators impose price caps and affordability board actions on Amgen's drug products.
-
Robert A. Bradway Operational
Robert A. Bradway serves as the CEO and Chairman of Amgen, actively leading its performance.
-
Veeva Systems Structural
Veeva provides clinical trial and CRM platforms that Amgen utilizes for operational efficiencies and collaboration.
-
Invesco Structural
Invesco holds a large, persistent investment position in Amgen stock.
-
Margaret Faul Structural
Margaret Faul is employed as a Vice President at Amgen.
-
Peter Griffith Structural
Peter Griffith serves as the Chief Financial Officer (CFO) of Amgen.
-
Pirow Bekker Transactional
Amgen acquired ChemoCentryx, the company that employed Pirow Bekker.
-
Mizuho Securities Operational
Mizuho Securities influences Amgen's stock valuation by issuing positive price target recommendations.
-
David Reese Structural
David Reese holds a senior executive role (EVP & CTO) at Amgen, demonstrating deep functional integration.
-
Medicare Structural
Medicare regulates Amgen's pricing and sets benchmarks for drug costs under the Inflation Reduction Act.
-
Astellas Pharma Operational
Amgen and Astellas Pharma engage in strategic collaborations.
-
MCK Structural
MCK functions as a key distributor and wholesaler for Amgen, upon which Amgen relies for revenue concentration.
-
Sanofi Operational
Sanofi and Amgen are direct competitors operating in the biopharma sector, vying for market leadership in dyslipidemia treatment.
-
Donald Trump Operational
Trump leverages his political influence and policy proposals, including tariffs and drug pricing agreements, to impact Amgen's market operations and business outlook.
-
Mizuho Transactional
Mizuho published a report that raised its price objective for Amgen, representing a specific market assessment of Amgen's value.
-
Ligand Pharmaceuticals Operational
Ligand Pharmaceuticals and Amgen maintain an ongoing partnership for drug development.
-
Amundi Transactional
Amundi increased its investment stake in Amgen shares.
History
Events by the month they beganOctober 2026
9 events- Laurus Labs is shifting focus from building to filling capacity and may participate in Amgen's supply chain.
- Reports on market moves involving Nike, Amgen, and Investopedia, amidst the ongoing Iran conflict.
- A guide on retirement income strategies was provided, noting strong dividend coverage cushions for Procter & Gamble and Amgen.
- Major pharmaceutical companies are competing for investment capital.
- Amgen and Eli Lilly committed to adopting Veeva's CRM platform, while Jim Cramer discussed Veeva's recovery from AI fears.
- Amgen announced funding initiatives aimed at promoting vision care.
- Several financial firms acquired or boosted their holdings in Amgen shares on October 7, 2026.
- AbbVie, Amgen, Micron Technology, and NetApp all showed strength in the stock market on October 7, 2026.
- Companies including ConocoPhillips, Amgen, Procter & Gamble, Coca-Cola, Texas Instruments, and Qualcomm are noted as part of the SCHD portfolio.
September 2026
30 events- Amgen and Merck are currently competing against each other in the market for investor capital.
- Amgen, City of Hope, and the California Community Foundation are involved in a life sciences and bioscience economic summit held in Downtown Los Angeles.
- The EPA recognized Amgen's green chemistry efforts, involving VP Margaret Faul, who previously worked at Eli Lilly.
- Sanofi removed Sjögren's from frexalimab and Novartis discontinued iscalimab in Sjögren's.
- Amgen and Deloitte are cited as examples of companies undergoing industry transformation.
- Amgen acquired Horizon Therapeutics, a company whose portfolio included a drug discovered by AstraZeneca.
- Berkshire Hathaway disclosed a large share purchase of Amgen on September 22, 2026.
- Several biotech companies reported clinical trial setbacks, including Argenx and Immunovant, while Sling Therapeutics' drug was compared to offerings from Viridian and Amgen.
- Both Amdocs and Amgen are currently subject to analyst reviews.
- Analyst upgrades and downgrades are affecting the stock performance of Amgen and CF Industries.
- Amgen and Novartis have developed similar drugs aimed at treating heart conditions.
- A rival's trial failure has challenged the shared scientific hypothesis between Amgen and Novartis.
- Novartis' drug failure has negatively impacted Amgen's financial outlook.
- The market is reacting to the news of Novartis' drug trial failures, specifically impacting Amgen's stock performance on the Nasdaq exchange.
- Amgen discusses biotech and pharma trends with Wells Fargo, where Thomas Dittrich serves as the company's Chief Financial Officer.
- Cantor Fitzgerald and other analyst firms issued ratings on Amgen stock, which is listed on the Nasdaq exchange.
- Barclays raises S&P 500 target, Amgen stock slumps after trial failure, and oil prices rise due to escalating Middle East hostilities.
- Novartis and Amgen stocks are declining, putting pressure on the Dow Jones Industrial Average due to their shared focus on cholesterol-targeting drugs.
- Reports on the top holdings of various healthcare and biotech ETFs, listing major pharmaceutical companies like Eli Lilly, Amgen, and Johnson & Johnson.
- Amgen and AstraZeneca co-developed the severe asthma drug TEZSPIRE, prompting an analyst to raise the price target.
- Amgen's stock price was impacted by clinical trial disappointments, while Brent crude influenced S&P 500 market movement.
- Amgen and AstraZeneca announced a collaborative development of a combination therapy.
- Joint drug trial success boosts Amgen stock.
- Geopolitical risk drives energy prices due to Iranian regime action, while clinical failures impact biotech stocks and Dell Technologies gains investor favor.
- GSK and Amgen are major biopharma players.
- The biotech sector is experiencing a downturn due to drug failures, impacting companies like Amgen and Eli Lilly.
- Market activity was monitored by representatives involving Amgen and Broadcom.
- Amgen and Microsoft are top holdings in an ETF.
- Norges Bank, Cantor Fitzgerald, Bank of America, and Scotiabank announced new stakes and target price boosts for Amgen.
- Amgen presented findings at the European Society of Cardiology Congress in Munich.
August 2026
7 events- Pfizer, Merck, and Amgen are large-cap drugmakers with significant operations in the United States.
- Amgen and AstraZeneca partnered on a Phase 3 CROSSING trial for the drug TEZSPIRE.
- Amgen and Eli Lilly offer treatments for thyroid eye disease, with Lilly's pipeline requiring regulatory approval.
- Both Microsoft and Amgen are major dividend payers currently under market scrutiny.
- Mikey Taylor graduated from Newbury Park High School and is running for Thousand Oaks City Council, while Karen Arreola worked at Amgen.
- Healthcare stocks surged to record highs on August 19, 2026, amid market excitement over drug breakthroughs involving Moderna, Amgen, and Merck.
- Amgen is reportedly interested in BioCryst Pharmaceuticals, which operates in the rare-disease market, as a potential acquisition target.
Show 2 earlier months
July 2026
1 eventJune 2026
13 events- Amgen Inc. trades on the NASDAQ stock exchange.
- A group of major pharmaceutical companies, including AbbVie, Bristol-Myers Squibb, Amgen, Pfizer, Moderna, and Merck, are noted as peers operating in the highly regulated pharmaceutical sector.
- Major pharmaceutical companies, including Pfizer, Amgen, Eli Lilly, and Novo Nordisk, are leading the market in next-generation GLP-1 drugs for weight loss and diabetes.
- Geode Capital Management increased its stake in Amgen stock and filed the disclosure with the SEC.
- AI stocks are benefiting from Trump-era tariffs, with Morningstar and ClearBridge providing market analysis on growth and upside potential.
- Trump's oil and gas pledges benefit US stocks, specifically impacting Pfizer.
- Intuit provides financial management services including TurboTax, Mailchimp, and Credit Karma, alongside developing innovative medicines.
- Royalty Pharma acquired a royalty interest in Amgen's drug Imdelltra.
- Trump's tariff plan caused markets to tank, affecting company Flo.
- Pharmaceutical companies are adopting AI for clinical data gathering, product promotion, and prototyping.
- RFK Jr.'s appointment as HHS Secretary is creating pressure as Medicare price setting and Part D redesign impact the sales and operations of major pharmaceutical companies including Pfizer, Amgen, J&J, Merck, and Eli Lilly.
- Multiple companies, including Eli Lilly, Amgen, Ionis, and Novartis, are developing advanced experimental drugs for heart disease, including those targeting Lp(a).
- Amgen filed required reports with the Securities and Exchange Commission on June 16, 2026.